Cimzia's setback paves way for other TNF inhibitors in Crohn's disease.

TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. J Neuroinflammation (2008) 3.19

SGLT2 inhibitors race to enter type-2 diabetes market. Nat Biotechnol (2012) 2.02

First CRISPR-Cas patent opens race to stake out intellectual property. Nat Biotechnol (2014) 1.81

Report claims no yield advantage for Bt crops. Nat Biotechnol (2009) 1.78

Gene therapy finds its niche. Nat Biotechnol (2011) 1.70

New class PCSK9 blockers stride into cholesterol market. Nat Biotechnol (2015) 1.70

Biogen and UPenn join forces to commercialize gene therapies. Nat Biotechnol (2016) 1.56

Report blames GM crops for herbicide spike, downplays pesticide reductions. Nat Biotechnol (2010) 1.52

EGFR inhibitors embrace KRAS. Nat Biotechnol (2008) 1.45

FDA approves 'farmaceutical' drug from transgenic chickens. Nat Biotechnol (2016) 1.39

Nature Biotechnology's academic spinouts of 2016. Nat Biotechnol (2017) 1.38

Next generation flu vaccine boosted by Chiron debacle. Nat Biotechnol (2004) 1.38

CAR-T cells forge ahead, Novartis reorganizes. Nat Biotechnol (2016) 1.28

Amgen swallows Micromet to BiTE into ALL market. Nat Biotechnol (2012) 1.27

Immune-checkpoint inhibitors march on, now in combinations. Nat Biotechnol (2014) 1.23

First Axl inhibitor enters clinical trials. Nat Biotechnol (2013) 1.22

Firms combine experimental cancer drugs to speed development. Nat Biotechnol (2010) 1.22

FDA approvals usher in the post-interferon era in HCV. Nat Biotechnol (2014) 1.18

New Merck and Vertex drugs raise standard of care in hepatitis C. Nat Biotechnol (2011) 1.17

Amgen's bispecific antibody puffs across finish line. Nat Biotechnol (2015) 1.17

TeGenero fiasco prompts regulatory rethink. Nat Biotechnol (2006) 1.16

Duchenne muscular dystrophy drugs at the crossroads, as newer agents advance. Nat Biotechnol (2016) 1.13

Companies in rapid pursuit of Btk immunokinase. Nat Biotechnol (2012) 1.08

Cautious optimism surrounds early clinical data for PD-1 blocker. Nat Biotechnol (2012) 1.07

Fresh from the biologic pipeline-2009. Nat Biotechnol (2010) 1.05

Amgen punts on deCODE's genetics know-how. Nat Biotechnol (2013) 1.05

Proof of concept for next-generation nanoparticle drugs in humans. Nat Biotechnol (2012) 1.04

Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol (2013) 1.04

Big oil turns on biofuels. Nat Biotechnol (2013) 1.01

Genentech raises stakes on PARP inhibitors. Nat Biotechnol (2006) 1.01

Milestone approval lifts Illumina's NGS from research into clinic. Nat Biotechnol (2014) 0.97

Can 'double blockbuster' strengthen Amgen's backbone? Nat Biotechnol (2008) 0.95

Amgen's angiopoietin blocker fails in ovarian cancer. Nat Biotechnol (2015) 0.94

Tysabri raises alarm bells on drug class. Nat Biotechnol (2005) 0.93

First approval in sight for Novartis' CAR-T therapy after panel vote. Nat Biotechnol (2017) 0.92

Doubts surround link between Bt cotton failure and farmer suicide. Nat Biotechnol (2009) 0.91

Doubts raised over 'read-through' Duchenne drug mechanism. Nat Biotechnol (2013) 0.91

Pivotal trials for β-secretase inhibitors in Alzheimer's. Nat Biotechnol (2015) 0.90

J&J's billion dollar punt on anti-amyloid antibody. Nat Biotechnol (2009) 0.87

Apple moves on health, drug developers shift into smart gear. Nat Biotechnol (2014) 0.87

Illumina claims $1,000 genome win. Nat Biotechnol (2014) 0.87

Amgen announces oncolytic virus shrinks tumors. Nat Biotechnol (2013) 0.85

Commercial interest grows in glycan analysis. Nat Biotechnol (2007) 0.84

IDO inhibitors move center stage in immuno-oncology. Nat Biotechnol (2015) 0.83

Recasting natural product research. Nat Biotechnol (2012) 0.83

Third Tysabri adverse case hits drug class. Nat Rev Drug Discov (2005) 0.83

Small molecule challenges dominance of TNF-alpha inhibitors. Nat Biotechnol (2008) 0.83

First oncolytic virus edges towards approval in surprise vote. Nat Biotechnol (2015) 0.83

Omics-driven startups challenge healthcare model. Nat Biotechnol (2015) 0.82

Bad medicine. Nat Biotechnol (2007) 0.82

Genentech obtains proof of concept for hedgehog inhibition. Nat Biotechnol (2009) 0.82

Investors start backing hearing loss treatments. Nat Biotechnol (2013) 0.82

Glial cells on the radar. Nat Biotechnol (2009) 0.82

Calamitous HCV trial casts shadow over nucleoside drugs. Nat Biotechnol (2012) 0.82

Footrace to clinic heats up for T-cell nuclear receptor inhibitors. Nat Biotechnol (2013) 0.82

EU to review rare disease drugs market exclusivity. Nat Biotechnol (2004) 0.81

Pharma consolidates its grip on post-antibody landscape. Nat Biotechnol (2007) 0.81

Antibiotics au naturel. Nat Biotechnol (2006) 0.80

Genentech to salvage anti-MET antibody with subgroup analysis. Nat Biotechnol (2014) 0.80

Exosome cancer diagnostic reaches market. Nat Biotechnol (2016) 0.80

Kenyan dispute illuminates bioprospecting difficulties. Nat Biotechnol (2004) 0.79

Cardiac stem cell therapies inch toward clinical litmus test. Nat Biotechnol (2013) 0.79

Industry pursues co-stimulatory receptor immunomodulators to treat cancer. Nat Biotechnol (2013) 0.79

First integrin inhibitor since Tysabri nears approval for IBD. Nat Biotechnol (2014) 0.79

Positive clinical data in Parkinson's and ischemia buoy gene therapy. Nat Biotechnol (2007) 0.78

Antiinfective biotechs face partnering gap. Nat Biotechnol (2005) 0.78

Making green. Nat Biotechnol (2009) 0.78

Second oral MS drug wins FDA nod. Nat Biotechnol (2013) 0.78

CETP inhibitors boost 'good' cholesterol to no avail. Nat Biotechnol (2016) 0.78

Protein chip companies turn to biomarkers. Nat Biotechnol (2005) 0.78

First generic biologics finally approved. Nat Rev Drug Discov (2006) 0.78

Despite slow progress, bispecifics generate buzz. Nat Biotechnol (2016) 0.77

Monoclonal T-cell receptor drugs pique pharma's interest. Nat Biotechnol (2013) 0.77

Cancer centers zero in on exceptional responders. Nat Biotechnol (2014) 0.77

RaNA therapeutics. Nat Biotechnol (2012) 0.77

First cystic fibrosis drug advances towards approval. Nat Biotechnol (2011) 0.76

First-in-class cancer therapeutic to stimulate natural killer cells. Nat Biotechnol (2006) 0.76

Merck's statin first to receive over-the-counter status. Nat Rev Drug Discov (2004) 0.76

Fast track to MS drug. Nat Biotechnol (2004) 0.76

The business of making vaccines. Nat Biotechnol (2005) 0.76

EPO neem patent revocation revives biopiracy debate. Nat Biotechnol (2005) 0.76

Stem cell therapy clears first hurdle in AMD. Nat Biotechnol (2014) 0.76

Insomniacs get new mechanism sleep drug Belsomra. Nat Biotechnol (2014) 0.76

Anti-CD20 antibody wows in multiple sclerosis. Nat Biotechnol (2015) 0.76

Drug makers target ubiquitin proteasome pathway anew. Nat Biotechnol (2015) 0.76

Drug developers refocus efforts on RAS. Nat Biotechnol (2016) 0.76

Immuno-oncology moves beyond PD-1. Nat Biotechnol (2015) 0.75

Firms chase diabetic inflammation with anti-IL-1beta antibodies. Nat Biotechnol (2010) 0.75

Industry continues dabbling with open innovation models. Nat Biotechnol (2011) 0.75

Synthetic biology firms pivot from biofuels to cheap biologics. Nat Biotechnol (2016) 0.75

Safety profiles come to fore as more drugs approach MS market. Nat Biotechnol (2012) 0.75

Belgian biotech's clot-buster approved for aging eyes. Nat Biotechnol (2012) 0.75

Abbott outbids Biogen for Facet's multiple sclerosis antibody. Nat Biotechnol (2010) 0.75

Roche backs Aileron's stapled peptides. Nat Biotechnol (2010) 0.75

Vaccine market boosters. Nat Biotechnol (2009) 0.75

National Academies relax stance on germline edits. Nat Biotechnol (2017) 0.75

Grail to pour $1 billion into blood test to detect early cancer. Nat Biotechnol (2017) 0.75

Drugmakers plow more resources into autism. Nat Biotechnol (2013) 0.75

Pertuzumab to bolster Roche/Genentech's breast cancer franchise? Nat Biotechnol (2011) 0.75

Flu vaccine makers upgrade technology--and pray for time. Nat Biotechnol (2009) 0.75

EMEA struggles with need to restructure. Nat Biotechnol (2003) 0.75